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Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disease in older people. Despite considerable efforts
to find a cure for AD, there is a 99.6% failure rate of clinical trials for AD drugs, likely because AD patients cannot
easily be identified at early stages. This project investigated machine learning approaches to predict the clinical state of
patients in future years to benefit AD research. Clinical data from 1737 patients was obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database and was processed using the “All-Pairs” technique, a novel methodology created
for this project involving the comparison of all possible pairs of temporal data points for each patient. This data was then
used to train various machine learning models. Models were evaluated using 7-fold cross-validation on the training dataset
and confirmed using data from a separate testing dataset (110 patients). A neural network model was effective (mAUC =
0.866) at predicting the progression of AD on a month-by-month basis, both in patients who were initially cognitively normal
and in patients suffering from mild cognitive impairment. Such a model could be used to identify patients at early stages of
AD and who are therefore good candidates for clinical trials for AD therapeutics.
1 Introduction
Alzheimer’s disease (AD) is the most common neuro-
degenerative disease in older people. [1, 2] AD takes a signifi-
cant toll on patients’ daily lives, causing a progressive decline in
their cognitive abilities, including memory, language, behavior,
and problem solving. [3–6] Changes to AD patients’ cognitive
abilities often start slowly and become more rapid over time. [7,
8] Doctors and other caregivers monitor the progression of AD
in patients by evaluating the degree of decline in the patients’
cognitive abilities [9], which are often divided into 3 general
categories: cognitively normal (NL), mild cognitive impairment
(MCI), and dementia. [5, 10] Patients with MCI and dementia
both suffer from reduced cognitive abilities, but MCI has a less
severe effect on everyday activities, and patients suffering from
dementia often have additional symptoms such as trouble with
reasoning or impaired judgment. [11, 12]
Unfortunately, there is no cure for AD at this time, and progress
on identifying a cure has been slow. [10] None of the five medi-
cations currently approved by the FDA to treat AD have been
shown to delay or halt its progression. [9] Instead, they only tem-
porarily improve patients’ symptoms. [9, 13, 14] And, the most
recently approved medication is just the combination of two
existing drugs for treating AD, donepezil and memantine, which
were approved by the FDA 23 and 16 years ago, respectively.
[14] Despite considerable efforts to find a cure for AD, there
is a 99.6% failure rate of clinical trials for AD drugs. [13, 15]
In early 2018 alone, two groups ended their AD clinical trials
because their drugs failed to prevent the progression of AD. [16,
17] The difficulty in finding treatments for AD is most likely a
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combination of uncertainty over the cause of AD and the fact
that AD patients cannot easily be identified at early stages. [10,
13, 18] Even the FDA recognizes the importance of identifying
patients who are at risk of developing AD but who don’t have
any noticeable cognitive impairment. [19] For this reason, AD
research would benefit from the ability to use current medical
data to predict the mental state of patients in future years in
order to identify patients who are good candidates for clinical
trials before they become symptomatic. [2, 10, 13, 20, 21]
Several different types of data have been identified that are
relevant to assessing the mental state of AD patients and the
progression of AD in general. One of the largest genetic risk
factors for AD is the presence of 1 or 2 copies of the 4 allele
of the APOE gene, which encodes a particular variant of the
enzyme Apolipoprotein E. [5] Physical changes to the brain
have also been shown to be correlated with the progression of
AD. For example, a decline in neurogenesis in the hippocampus
is one of the earliest changes to brain physiology seen in AD
patients and is thought to underlie cognitive impairments associ-
ated with AD. [6] The progression of AD also accelerates the
normal atrophy of brain tissue caused by aging, as evidenced by
increased enlargement of the ventricles of the brain over time.
[22] One study demonstrated a 4-fold difference in the rate of
ventricle enlargement in AD patients and normal controls over a
six-month interval. [22] Cognitive tests have also been widely
used for early detection of AD. [8] Several commonly used tests,
such as ADAS11 and ADAS13, are based on the Alzheimer’s
Disease Assessment Scale (ADAS), which is a brief cognitive
test battery that assesses learning and memory, language produc-
tion, language comprehension, constructional praxis, ideational
praxis, and orientation. [23, 24] ADAS11 scores range from 0 to
70, and ADAS13 scores range from 0 to 85, with higher scores
indicating more advanced stages of AD. [24] Similar cognitive
tests, such as the Mini-Mental State Examination (MMSE), the
Rey Auditory Verbal Learning Test (RAVLT), and the Functional
Activities Questionnaire (FAQ) have also been used to assess
the progression of AD in individual patients. [25, 26] ADAS
has been found to be more precise than the MMSE [27], and the
ar
X
iv
:1
90
3.
07
51
0v
2 
 [c
s.L
G]
  2
2 M
ar 
20
19
2RAVLT only addresses verbal recall [28], thus providing less
diagnostic information than either of the other two. Similarly,
the FAQ only assesses a patients’ ability to perform certain tasks
[29] and therefore is more limited in scope than the MMSE and
ADAS.
In recent years, machine learning techniques have been applied
to the diagnosis of AD patients with great success. For example,
Esmaeilzadeh et al. achieved an accuracy of 94.1% using 3D
convolutional neural networks to diagnose AD on a dataset with
841 patients. [30] Similar results were obtained by Long et al.,
who used a support vector machine to diagnose AD based on
an MRI scan dataset (n = 427 patients; mean best accuracy =
96.5%) [31] and Zhang et al., who used MRI scans, FDG-PET
scans, and CSF biomarkers to diagnose AD (n = 202 patients;
AD vs. NL accuracy = 93.2%, MCI vs. NL accuracy = 76.4%).
[32] However, the focus of these earlier studies was to use
current medical data to diagnose a patient’s present cognitive
state, in effect demonstrating that a computer can replicate a
doctor’s clinical decision-making. What is needed is a way to
use machine learning to predict future diagnoses of AD patients.
[10]
2 Methods
2.1 ADNI Data
Data used in the preparation of this article were obtained
from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database (adni.loni.usc.edu). The ADNI was launched in 2003
as a public-private partnership, led by Principal Investigator
Michael W. Weiner, MD. The primary goal of ADNI has been to
test whether serial magnetic resonance imaging (MRI), positron
emission tomography (PET), other biological markers, and clin-
ical and neuropsychological assessment can be combined to
measure the progression of mild cognitive impairment (MCI)
and early Alzheimer’s disease (AD).
The ADNI study has been divided into several phases, includ-
ing ADNI-1, ADNI-GO, and ADNI-2, which started in 2004,
2009, and 2011, respectively. ADNI-1 studied 800 patients, and
each subsequent phase included a mixture of new patients and
patients from the prior phase who elected to continue to partic-
ipate in the study. The ADNI patient data was pre-processed
to flag missing entries and to convert nonnumeric categories
(such as race) into numeric data. Data was sorted into three
datasets (LB1, LB2, and LB4) based on criteria established by
The Alzheimer’s Disease Prediction Of Longitudinal Evolution
(TADPOLE) Challenge (https://tadpole.grand-challenge.org/).
[10] The LB2 and LB4 datasets consist of data from 110 pa-
tients who participated in ADNI-1, continued to participate in
ADNI-GO/ADNI-2, and who were not diagnosed with AD as
of the last ADNI-1 time point. Specifically, LB2 contains all
observations of these patients from ADNI-1, and LB4 contains
all observations of these patients from ADNI-GO/ADNI-2. The
LB1 dataset consists of ADNI data for all remaining patients (n
= 1737). Generally speaking, LB1 was used as a training and
validation dataset, while LB2 and LB4 were later used to test the
ability of machine learning models to predict the progression of
AD on an independent patient population.
2.2 All-Pairs Technique
Data from LB1 was then further processed using a novel method-
ology developed for this project called the All-Pairs technique,
which can be summarized as follows: Let R be the number of
patients in the dataset and B be the number of biomarkers (or
other clinical data) being evaluated as features. For each patient
Pi (1 ≤ i ≤ R), the ADNI database includes Li separate exami-
nations by a physician. Then, Ei, j, the jth examination of the ith
patient, can be defined as a multidimensional vector as follows:
Ei, j = [di, j, bi, j,1, bi, j,2, ..., bi, j,B, ci, j]
where di, j is the date of the examination, bi, j,k (1 ≤ k ≤ B) are
different biomarkers (or other clinical data), and ci, j is the clini-
cal state of the patient (normal, MCI, or dementia) as measured
during that examination. The All-Pairs technique transforms this
examination data to generate a feature array X and target array Y
that are used to train the machine learning models. Specifically,
for every i, ja, jb, where 1 ≤ i ≤ R and 1 ≤ ja < jb ≤ Li, a row
of X and a corresponding cell of Y are calculated:
Xrow = [di, jb − di, ja , bi, ja,1, bi, ja,2, . . . , bi, ja,B, ci, ja ]
Ycell = ci, jb
This approach can be extended from pairs of examinations
( ja, jb) to triplets ( ja, jb, jc) as follows:
Xrow = [di, jc − di, jb , di, jb − di, ja , bi, jb,1, . . . ,
bi, jb,B, ci, jb , bi, ja,1, . . . , bi, ja,B, ci, ja ]
Ycell = ci, jc
Individual rows and cells are then assembled to create the X and
Y arrays that are used for training of the machine learning model
as well as cross-validation studies.
2.3 Evaluation using LB2 and LB4 Datasets
In the case of LB2, each examination can be characterized by the
same vector Ei, j as used for the LB1 dataset. However, because
the LB2 data is only used to test the machine learning models
and not for training, no comparison between examinations is
performed. Instead, Ei, j is transformed into the input vector
by replacing the di, j term with a time variable that represents
the number of months into the future that the machine learning
model should make a prediction. Specifically, for each patient
Pi in LB2, the machine learning algorithm is applied to a series
of input vectors of the form:
[t, bi, j,1, bi, j,2, . . . , bi, j,B, ci, j]
where t is the time variable. Input vectors are generated based
on each patient’s last three examinations in LB2, or for all of the
examinations if the patient has less than three. The probabilities
calculated by the machine learning algorithm based on these
examinations are averaged to generate predicted probabilities
for patient Pi at time t. When comparing the model’s predictions
3Category Feature Name Description
Genetic APOE4 The APOE4 biomarker measures the number of copies (0, 1, or 2) of the 4 allele of the
gene encoding the enzyme Apolipoprotein E. This allele is the strongest genetic risk factor
for AD. [5]
Hippocampus
Physical
Ventricles/ICV
Physical measurements, like the volume of the hippocampus [6] and the ventricles [22],
can be used to assess the effect AD has on the brain.
ADAS11
ADAS13
FAQ
MMSE
Behavioral
RAVLT (4 types)
Cognitive tests have been widely applied for early detection of AD. [33]
Race
Demographic
Age
Demographic data can be used to account for general trends in a population.
Table 1: Features from the ADNI Dataset Used in this Study
against the actual diagnoses in LB4, t is set to the time difference
between the applicable exam in LB2 and the applicable exam in
LB4. For the time courses shown in Figures 6 and 7, t is set to
an integer between 1 and 84, inclusive.
2.4 Features
The features analyzed by the machine learning models consisted
of 13 biomarkers or other types of clinical data present in the
ADNI dataset, all of which have been cited in published pa-
pers as correlating with AD progression. These 13 features
are summarized in Table 1 and include genetic biomarkers
(APOE4), physical biomarkers (ventricular volume/ICV ratio,
hippocampal volume), the results of behavioral tests (ADAS13
and ADAS11 scores, FAQ score, MMSE score, and 4 types of
RAVLT scores), and basic demographic information (age and
race). As described above, two additional features that were
generated during pre-processing of the data using the All-Pairs
technique were also included in the models, namely, the clin-
ical diagnosis at the earlier of two examinations and the time
difference between examinations.
3 Results
3.1 Model Performance
A flowchart summarizing the overall methodology for training
and evaluating machine learning models is shown in Figure 1.
Various machine-learning classifiers, including support vector
machines, logistic regression, gradient boosting classifiers, ran-
dom forests, multilayer perceptron neural networks, and re-
current neural networks, were implemented using the Python
libraries Scikit-learn and Keras (backed by TensorFlow). Each
classifier was then evaluated on the processed data derived from
LB1 using 7-fold cross-validation.
Figure 1: Project Flowchart
4Variable Meaning 8-featuretraining group
11-feature
training group
15-feature
training group
DX Earlier Diagnosis X X X
ADAS13 13-item Alzheimer’s Disease Assessment
Scale
X X X
Ventricles Ventricular Volume X X X
AGE Age X X X
FAQ Functional Activities Questionnaire X X
PTRACCAT Race X X X
Hippocampus Hippocampal Volume X X X
APOE4 # of APOE4 Alleles X X X
MMSE Mini-mental state examination X X
ADAS11 11-item Alzheimer’s Disease Assessment
Scale
X X
RAVLT_immediate Rey Auditory Verbal Learning Test — To-
tal number of words memorized over 5 tri-
als
X
RAVLT_learning Rey Auditory Verbal Learning Test —
Number of words learned between trial 1
and trial 5
X
RAVLT_forgetting Rey Auditory Verbal Learning Test —
Number of words forgotten between trial 5
and trial 6
X
RAVLT_perc_forgetting Rey Auditory Verbal Learning Test — Per-
centage of words forgotten between trial 5
and trial 6
X
N/A Time Difference X X X
Table 2: Features from the ADNI Dataset Used to Train the MLP and RNN
Figure 2: Performance of Various Machine Learning Models (100 Random Splits of 1737-Patient Training Dataset)
5The effectiveness of each classifier was measured using a spe-
cialized version of an ROC-AUC (Receiver Operating Charac-
teristic Area Under the Curve) score for multiclass classification
(“mAUC score”), as previously described by Hand and Till.
[34] The ROC-AUC score is a balanced metric for classifiers
that considers both the true positive rate (percentage of actual
positives that are called correctly) and the false positive rate
(percentage of actual negatives that are called incorrectly). The
mAUC variant of this score takes all ordered pairs of categories
(i, j), measures the probability that a randomly selected element
from category i would have a higher estimated chance of being
classified as category i than a randomly selected element from
category j, and averages all of these probabilities. A classifier
that works perfectly would have an mAUC score of 1; a classifier
that guessed randomly would result in an mAUC score of 0.5.
In the end, two classifiers, a multilayer perceptron implemented
in Scikit-learn (“MLP”) and a recurrent neural network imple-
mented in Keras (“RNN”) were found to have the best perfor-
mance in the cross-validation studies. Both of these classifiers
are types of neural networks. An MLP consists of a layer of
input nodes, a layer of output nodes, and one or more hidden
layers between the input and output layers. Each input vector
is fed into the input nodes, and the value of each node in every
other layer is dependent on the values of the nodes in the pre-
vious layer. Like an MLP, an RNN consists of multiple nodes
organized into layers, but the outputs of some of the hidden lay-
ers are fed back into the same layer so that earlier input vectors
can influence the outputs for later input vectors. This allows the
RNN to “remember” earlier inputs, which has been shown to be
particularly useful when analyzing data consisting of multiple
observations taken at different time points. [35, 36]
To further investigate the MLP and the RNN and see if the
performance of the MLP and RNN could be further improved
by optimizing the training protocol, six variants of each of the
neural networks were generated to examine the effects of chang-
ing the number of features being examined (8, 11, and 15) and
whether the All-Pairs technique was applied to pairs of patients’
doctors’ visits or triplets of visits. Table 2 details which features
were included in the 8, 11, and 15-feature training groups. The
columns in Table 2 labelled “Variable” and “Meaning” provide
the name of each feature as it appears in the ADNI dataset as
well as the corresponding description for each feature, respec-
tively.
Table 3 shows the resulting mAUC scores after training and
testing the 12 models on LB1-derived data using 7-fold cross-
validation, as well as the standard deviations for the testing
mAUC scores. The best performing model was the MLP trained
on 8 features and triplets of time points, as it had the highest
testing mAUC score. This model is highlighted in blue in Table
3. However, the differences among all of these models are
quite small and in many cases well within 1 standard deviation
(s.d.), suggesting that some of the variability between the scores
might be due to random chance rather than actual differences
in predictive performance. Additionally, because the training
and testing of neural networks, as well as the cross-validation
process, relies to some extent on algorithms that utilize random
numbers, the scores in the table will change slightly each time
that the models are subjected to cross-validation.
Model TrainmAUC
Test
mAUC
Test
S.D.
8 Features, RNN, pairs 0.9390 0.9318 0.0144
11 Features, RNN, pairs 0.9483 0.9357 0.0122
15 Features, RNN, pairs 0.9504 0.9320 0.0148
8 Features, MLP, pairs 0.9490 0.9418 0.0073
11 Features, MLP, pairs 0.9543 0.9523 0.0083
15 Features, MLP, pairs 0.9550 0.9515 0.0083
8 Features, RNN, triplets 0.9649 0.9158 0.0118
11 Features, RNN, triplets 0.9724 0.9230 0.0118
15 Features, RNN, triplets 0.9697 0.9357 0.0236
8 Features, MLP, triplets 0.9608 0.9631 0.0133
11 Features, MLP, triplets 0.9662 0.9505 0.0129
15 Features, MLP, triplets 0.9669 0.9481 0.0174
Table 3: Accuracy Metrics from Various Machine Learn-
ing Models (7-Fold Cross-Validation on 1737-Patient Train-
ing Dataset). MLP = multilayer perceptron implemented in
Scikit-learn; RNN = recurrent neural network implemented in
Keras/Tensorflow
In order to assess the performance of these models in a more
rigorous manner, each of the 12 models was also evaluated on a
series of random splits of the preprocessed LB1 dataset. For each
model, the preprocessed LB1 dataset was randomly separated
into a training dataset and testing dataset using a 70:30 ratio,
and this was repeated to create 100 pairs of training and testing
datasets that were then used to train and test the model. The
use of a large number of randomly generated splits produces
a distribution of mAUC scores that better reflects the overall
performance of the model and minimizes the effects of outliers.
The results are shown as box-and-whisker plots in Figure 2.
Using this more rigorous approach, the model with the highest
average mAUC score was an MLP trained on data with 15
features and with triplets of patients’ examinations, which had
an average mAUC score of 0.967 and a standard deviation of
0.0016. This model is highlighted in blue in Figure 2.
3.2 Prediction of Alzheimer’s Disease Progression
In order to assess real-world performance, select models were
also trained on the entire LB1 dataset (after processing with the
All-Pairs technique) and then evaluated on data derived from
LB2 and compared to actual diagnoses in LB4, asking whether
early biomarkers and other early clinical data for the 110 patients
in LB2 can predict their later diagnoses. The actual examination
dates in LB4 vary from patient to patient, but they generally
cover the 7-year period of ADNI-GO/ADNI-2. LB4 contains a
total of 417 examinations, or an average of 3.79 examinations
per patient. As in the cross-validation studies, the performance
of each model was assessed based on mAUC scores. Out of
the 12 previously discussed models, the 4 models that used 15
features were selected for testing against LB2/LB4, namely:
6Figure 3: Performance of Various Machine Learning Models
(110-Patient Testing Dataset, 5 Iterations)
1. MLP trained using pairs of examinations,
2. MLP trained using triplets of examinations,
3. RNN trained using pairs of examinations, and
4. RNN trained using triplets of examinations.
Hyper-parameter optimization was conducted for each of these
models, and each model was tested 5 times for each set of
parameters to minimize the impact of random variation inherent
in the neural network training process. In total, 27 different
sets of parameters were tested for each model, consisting of 3
possible values for the alpha parameter, 3 possible values for the
learning rate, and 3 possible values for the size of the hidden
layers. Figure 3 shows the results from the highest performing
version of each of the 4 models listed above.
The model and parameters with the best average mAUC score
was the MLP trained on 15 features using pairs of examinations,
which achieved an average score of 0.866 on the 110-patient
test dataset. This model is shown with a blue box in Figure 3.
This result represents an improvement over previously published
work using the ADNI dataset. In particular, Moore et al. [8]
achieved an mAUC score of 0.82 with a random forest classifier;
Ghazi et al. [35] achieved an mAUC score of 0.7596 with
an RNN; and Nguyen et al. [36] achieved an average mAUC
score of 0.86 with an RNN together with forward-filling data
imputation.
Figure 4 depicts a confusion matrix for this best performing
model, which provides a visual indication of how well the diag-
noses predicted by the model line up with the actual diagnoses.
The confusion matrix reveals two types of mistakes occasionally
made by the machine learning model: predicting a cognitively
normal diagnosis when a patient is actually diagnosed with MCI
and predicting an MCI diagnosis when a patient is actually diag-
nosed with dementia. These mistakes may both simply be the
result of a small error in how the time variable is applied by the
algorithm, which creates a lag in the diagnosis predictions.
Figure 4: Confusion Matrix Comparing Predicted Diagnosis
with Actual Diagnosis
Figure 5 shows a group of Receiver Operating Characteristic
(ROC) curves based on the output of the best performing model,
which measure how well the model can separate two groups:
patients with a particular diagnosis and patients with one of
the other diagnoses. Interestingly, the ROC score for the MCI
class is lower than the other two ROC scores, suggesting that
the model is having more difficulty separating patients with
MCI from the other two groups. Based on these individual
ROC scores, the model’s average mAUC score (0.866) could
be dramatically increased if the model’s ability to separate MCI
patients from non-MCI patients was improved.
Figure 5: ROC Curves Based on Output of Neural Network
The best performing model was also used to predict the future
diagnosis of normal, MCI, or dementia for all 110 patients in the
LB2/LB4 datasets on a month-to-month basis over an 84-month
(7-year) period, as shown in Figure 6. The model predicted
that some patients would remain normal over the entire 7-year
period, while others would progress from normal to MCI to
dementia.
7Figure 6: Month-by-Month Predicted Diagnosis for 110 Patients over 7 Years
8Figure 7: Predicted Likelihood of Diagnoses for 50 Random Patients over 7 Years
Time courses were also generated for a random subset of these
patients (n=50) showing how the likelihood of normal, MCI,
or dementia diagnoses is forecast to vary over the 84 months,
as shown in Figure 7. The color of each curve (green, yellow,
or red) indicates the most severe diagnosis actually received by
the patient (normal, MCI, or dementia, respectively) during the
7-year period. As can be seen in Figure 7, patients who remained
normal over the entire 84-month period generally received very
low predicted probabilities of MCI or dementia diagnoses from
the model. Similarly, patients who were diagnosed with de-
mentia at some point during this period generally received high
predicted probabilities of dementia from the model.
4 Conclusion
Previous work published by others has shown that machine
learning algorithms can accurately classify a patient’s current
cognitive state (normal, MCI, or dementia) using contempo-
raneous clinical data. [30–32] This project has extended this
previous work by looking at how past and present clinical data
can be used to predict a patient’s future cognitive state and by
developing machine learning models that can correlate clinical
data obtained from patients at one time point with the progres-
sion of AD in the future. Several of the machine-learning models
used in this project were effective at predicting the progression
of AD, both in cognitively normal patients and patients suffer-
ing from MCI. Additionally, a novel All-Pairs technique was
developed to compare all possible pairs of temporal data points
for each patient to generate the training dataset. By comparing
data points at different points in time, the All-Pairs technique
adds time as a variable and therefore does not require fixed time
intervals, which are unlikely to occur in “real-life” data. [37]
These techniques could be used to identify patients having high
AD risk before they are diagnosed with MCI or dementia and
who would therefore make good candidates for clinical trials for
AD therapeutics. Since the inability to identify AD patients at
early stages is believed to be one of the primary reasons for the
frequent failure of AD clinical trials, these techniques may help
increase the chances of finding a treatment for AD.
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